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Biodistribution and function of 
extracellular miRNA-155 in mice
Shashi Bala1, Timea Csak1, Fatemeh Momen-Heravi1, Dora Lippai1,*, Karen Kodys1, 
Donna Catalano1, Abhishek Satishchandran1, Victor Ambros2 & Gyongyi Szabo1
Circulating miRNAs can be found in extracellular vesicles (EV) and could be involved in intercellular 
communication. Here, we report the biodistribution of EV associated miR-155 using miR-155 KO 
mouse model. Administration of exosomes loaded with synthetic miR-155 mimic into miR-155 KO 
mice resulted in a rapid accumulation and clearance of miR-155 in the plasma with subsequent 
distribution in the liver, adipose tissue, lung, muscle and kidney (highest to lowest, respectively). 
miR-155 expression was detected in isolated hepatocytes and liver mononuclear cells of recipient 
KO mice suggesting its cellular uptake. In vitro, exosome-mediated restoration of miR-155 in Kupffer 
cells from miR-155 deficient mice augmented their LPS-induced MCP1 mRNA increase. The systemic 
delivery of wild type plasma to miR-155 KO mice also resulted in a rapid accumulation of miR-155 in 
the circulation and distribution to the liver and adipose tissue. In summary, our results demonstrate 
tissue biodistribution and biologic function of EV-associated miR-155.
MicroRNAs (miRNAs) are a class of non-coding RNAs that regulate gene expression1. miRNAs are 
highly stable and can be detected in various human body fluids, including peripheral blood, plasma, 
and serum2–4. Circulating/extracellular miRNAs are present either in extracellular vesicles (EV) (includ-
ing exosomes, microvesicles, and apoptotic bodies) or associated with non-membranous particles that 
include RNA inducing silencing complex (RISC) proteins (AGO proteins)5–7. Exosomes are of multive-
sicular bodies origin with a size range from 40–100 nm and express exosomal markers, including CD9, 
CD63, CD81, Alix, Flotillin-1 and Tsg1018. Microvesicles directly bud from the plasma membrane with 
a size range from 50–1000 nm and have no unique markers8. Currently consensus is still under develop-
ment regarding the origin and nomenclature of exosomes and microvesicles.
Multiple lines of evidence indicate that circulating miRNAs have the potential to be distributed into 
organs via the circulation9–11. miRNAs are found to be stable in the circulation and this property makes 
them attractive for biomarker discovery. miRNAs are also receiving interest given their potential as ther-
apeutic tools and targets in various diseases. Evidences suggest that extracellular vesicles (EV)/exosomes 
carry various cargos including nucleic acids (mRNA and non-coding RNA), proteins and lipids and serve 
as vehicles to transfer material between cells/organs6,12–14.
Exosomal meditated transfer of miRNA has been proposed to be a mode of intercellular commu-
nication11,15–17, and exosomes have been shown to play a role in inflammation and metastasis13,18–20. 
Moreover, exosomes have emerged as potential vehicles to deliver drugs, nucleic acids, and other mol-
ecules in vivo21–24. Studies have reported exosome-mediated delivery of siRNA into the brain and other 
organs25,26.
miR-155 is an inflammation associated miRNA that regulates inflammation and immune cell func-
tions at multiple levels27,28. Previously, we showed induction of miR-155 in the plasma and liver after 
administration of inflammatory signals via TLR9 ligand (CpG) followed by TLR4 ligand (LPS) chal-
lenges29. Further, using the ExoQuick isolation method, we found that miR-155 was associated with 
extracellular vesicles/exosomes in the plasma29.
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Though studies suggest that miRNAs are present in cell free forms, it is not clear if extracellular 
miRNAs in blood/plasma are present in physiologically relevant amounts to exert cell-to-cell signaling 
effects30. Little is known about the half-life and biodistribution of circulating miRNA. Using a miR-155 
knock-out (KO) mouse transfer model system, here, we report the half-life and biodistribution of miR-
155 mimic loaded in exosomes (exo-miR-155 mimic) and wild type plasma enriched in miR-155 (WT 
plasma). The latter represents both EVs and non-EV associated miR-155. Our results indicate a rapid 
accumulation of exosome-loaded miR-155 mimic (exo-miR-155 mimic) in the plasma of recipient miR-
155 KO mice with subsequent distribution to the liver, adipose tissue, lung, muscle, and kidney (highest 
to lowest, respectively). At the cellular level, miR-155 was detected in hepatocytes and liver mononu-
clear cells (MNCs; monocytes, lymphocytes and dendritic cells) of recipient miR-155 KO mice in vivo, 
suggesting successful uptake of exo-miR-155 mimic by various populations of liver cells. Functionally, 
exo-miR-155 mimic was able to induce MCP1 in Kupffer cells isolated from miR-155 KO mice in an in 
vitro co-culture system.
To mimic the half-life and distribution of miRNA naturally present in the plasma, we administered 
WT plasma (donor) to miR-155 KO (recipient) mice. Our results indicate detection of donor miR-155 
in plasma of recipient miR-155 KO mice and distribution to the liver and adipose tissue.
Results
Biodistribution of exosome-loaded miRNA-155 mimic in miRNA-155 deficient mice. Circulating 
miRNAs are associated with either proteins (Ago2)3,5 or extracellular vesicles including exosomes/
microvesicles31. Using filtration and ExoQuick isolation method we found that miR-155 was associated 
with extracellular vesicles in the plasma after CpG+ LPS treatment in wild type mice (Fig. 1A). However, 
little is known about the half-life and biodistribution of exosome/microvesicles (EV) associated miRNAs 
(EV-miRNAs) in vivo. Here, we established an exosome-based miR-155 mimic delivery system to study 
the biodistribution of EVs associated miRNA-155 using a miR-155 KO mouse model.
To deliver miR-155 mimic, CD63 enriched exosomes were isolated from murine B cells using 
immune-magnetic bead selection as described in the methods32. CD63-enriched exosomes have an aver-
age size of 84 nm as determined by Nanosight (Suppl. Fig. 1A) and showed a typical concave/mushroom 
like morphology under transmission electron microscopy (Suppl. Fig. 1B)22. To rule out the possibility 
that electroporation may adversely affect exosomes structural stability, exosomes before and after elec-
troporation were visualized by the electron microscopy. No significant differences in the structure of 
exosomes were found before and after electroporation (Suppl. Fig. 1B).
Exosomes isolated from B cells were enriched in CD63 and CD81 and free of any cellular protein 
contamination (Suppl. Fig. 1C). GRP78, an endoplasmic reticulum protein was present in the cells but 
absent in exosomes preparation (Suppl. Fig. 1C). Exosomes derived from B cells provided a suitable sys-
tem for miR-155 mimic delivery since we found very low levels of miR-155 at the baseline22. Compared 
to exosomes isolated from naïve cells, miR-155 expression was decreased in exosomes derived from 
treated B cells (IL-4 and CD40) (Suppl. Fig. 1D)22.
The electroporation of miR-155 mimic (mature form of miR-155) and not miRNA mimic negative 
control #1 (scrambled mimic) resulted in a significant increase of miR-155 in exosomes (Fig. 1B). Further, 
no induction of pro-inflammatory cytokines (TNFα , MCP1 and IL-1β ) both at the mRNA (Suppl. Fig. 
1E) and protein levels (Suppl. Fig. 1F) were found in liver mononuclear cells (MNCs) isolated from 
WT mice treated with scrambled miRNA mimic loaded exosomes. To reduce the possibility of miRNA 
being outside of exosomes after electroporation, RNAse A treatment was performed. Real-time PCR data 
indicates that the amount of miR-155 was reduced in the re-isolated exosomes after RNAse A treatment 
compared to RNAse A naïve exosomes, suggesting degradation of free floating miR-155 mimic (Suppl. 
Fig. 1G). Based on these observations, the miR-155 mimic loaded exosomes (exo-miR-155 mimic) rep-
resented a suitable vehicle for testing the in vivo biodistribution of extracellular miR-155. The detailed 
description of exosome generation is described in the methods (also in Suppl. Fig. 2).
Having confirmed by qPCR that exosomes loaded with scrambled mimic did not induce 
pro-inflammatory cytokines (TNFα , MCP1 and IL-1β ) in target cells (Suppl. Fig. 1E and F), we next 
performed in vivo experiments. Intravenous administration of exo-miR-155 mimic (100 μ l; ~2 × 108 par-
ticles/ 100 μ g exosomal protein) into miR-155 KO mice resulted in a ~15 fold increase in miR-155 levels 
in the plasma after 5 mins compared to naturally existing miR-155 plasma levels in wild type (WT) mice 
(Fig. 1C). By 30 mins, around 90% of miR-155 had disappeared from plasma and its levels in recipient 
miR-155 KO mice reached to the baseline miR-155 expression level of WT mice (Fig. 1C). This obser-
vation was specific to mice injected with exo-miR-155 mimic as no detectable levels of miR-155 was 
found in recipient miR-155 KO mice injected with scrambled mimic loaded exosomes (Fig. 1C–J). In 
perfused organs of recipient miR-155 KO mice, a peak in miR-155 levels was observed around 10 mins 
after exo-miR-155 mimic administration (Fig. 1C–H). Interestingly, we found that the kinetics of miR-
155 was very similar in the perfused organs and plasma of recipient miR-155 KO mice (Fig. 1C–H). 
When compared to WT mice, the amount of miR-155 in recipient miR-155 KO mice was highest in the 
liver, followed by adipose tissue, lung, muscle, and lowest in the kidney. In the liver and adipose tissue 
of recipient miR-155 KO mice, the amount of miR-155 was higher at 10 mins compared to baseline 
expression of miR-155 in WT mice and returned to the baseline WT expression after 40 mins (Fig. 1D,E). 
A moderate increase in miR-155 levels was observed in the brain of recipient miR-155 KO mice after 
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Figure 1. Biodistribution of exosome loaded miRNA-155 mimic in miRNA-155 KO mice. C57Bl/6 wild 
type female mice were either injected with saline or 2.5 mg/kg CpG DNA (i.p.) once a day for three days 
and on day 4 CpG treated mice received 0.5 mg/kg LPS for 3h and blood was isolated. Extracellular vesicles 
were isolated from plasma using filtration and ExoQuick and miR-155 levels were determined (A) B cells 
were treated with CD40 and IL-4 and exosomes were isolated using CD63 magnetic beads as described in 
the methods. Exosomes were electroporated with either scrambled mimic or miRNA-155 mimic and miR-
155 levels were determined after RNase A treatment. miR-155 levels were normalized to scrambled mimic 
loaded exosomes (B) 100 ul exosomes (loaded with scrambled mimic or miR-155 mimic) were injected (i.v) 
into miR-155 KO mice for indicated times and mice were perfused as described in the methods. miR-155 
levels in the plasma (C) liver (D) adipose tissue (E) lung (F) muscle (G) kidney (H) isolated hepatocytes (I) 
and mononuclear cells (J) was determined using real time qPCR. miR-155 levels were normalized to wild 
type saline treated mice. * indicates p < 0.05 versus scrambled mimic exosome treated KO mice. Synthetic 
spiked cel-miR-39 (A–C) or SnoRNA202 (D–J) was used to normalize the technical variations between the 
samples. Statistical analysis was performed using non-parametric Mann-Whitney test.
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10 mins, however it did not reach statistical significance due to sample variability (data not shown). No 
significant increase in miR-155 was observed in the thymus or heart.
To determine if exo-miR-155 mimic was delivered into cells, and not just to the interstitial space in 
the organs, we next evaluated miR-155 levels in isolated liver cell sub-populations. In hepatocytes and 
liver mononuclear cells (MNCs) of recipient miR-155 KO mice, a peak in miR-155 levels was found at 
10 mins followed by a rapid decline in its levels similar to what we found in perfused liver/organs (Fig. 
1I,J). No significant amount of miR-155 was found in spleen and bone marrow cells.
Biological function of miRNA-155 mimic loaded exosomes in Kupffer cells isolated from miR-
155 KO mice. To evaluate the effect of exo-miR-155 mimic delivered to liver cells of miR-155 KO 
mice, we performed in vitro studies. In vitro co-culture of exo-miR-155 mimic with primary hepatocytes 
and Kupffer cells isolated from miR-155 KO mice resulted in detectable levels of miR-155 in both cell 
types (compared to cells treated with scrambled mimic exosomes) (Fig. 2A,B). Relative to WT miR-155 
expression, introduction of exo-miR-155 mimic resulted in higher miR-155 expression in Kupffer cells 
than hepatocytes in miR-155 KO cells. (Fig. 2A,B). Also miR-155 levels in Kupffer cells isolated from 
miR-155 KO mice after co-culture with exo-miR-155 mimic were higher than the baseline miR-155 
expression of WT cells (Fig. 2B). Functionally, hepatocytes treated with exo-miR-155 mimic showed no 
further increase in MCP1 protein production compared to those treated with scrambled mimic loaded 
exosomes after LPS challenge (data not shown). The restoration of miR-155 in Kupffer cells isolated 
from miR-155 KO mice resulted in the induction of pro-inflammatory cytokines after LPS challenge 
(Fig. 2C,E). Kupffer cells treated with exo-miR-155 mimic showed a higher induction in MIP2 mRNA 
(Fig. 2C) and MCP1 (both at the mRNA and protein levels) compared to cells received exosomes with 
scrambled mimic after LPS challenge (Fig. 2D,E). The scrambled or exo-miR-155 mimic did not induce 
any inflammatory response in LPS naïve cells (Fig. 2D,E).
Biodistribution of wild type plasma in miR-155 KO mice. After observing a rapid biodistribution 
and organ and cellular uptake of exo-miR-155 mimic, we next evaluated the distribution of miR-155 
present in WT plasma (natural). WT plasma was generated from CpG+ LPS treated wild type mice and 
was enriched in miR-155 as we previously found29 (Fig. 1A). WT plasma was injected to miR-155 KO 
mice to determine the half-life and tissue distribution of natural miR-155. Intravenous administration of 
WT plasma (donor) (~150ul) into miR-155 KO (recipient) mice resulted in a ~ 4-fold increase in miR-
155 levels in the plasma after 5 mins compared to WT mice (Fig. 3A). A peak in miR-155 levels was 
observed in the plasma of recipient miR-155 KO mice as early as 5 mins and there was a ~50% decrease 
in its levels after 30 mins of administration (Fig. 3A). After 1h, miR-155 levels in the plasma of recipient 
miR-155 KO mice were reduced to the baseline expression of WT mice. By 4 hours, miR-155 was unde-
tectable in the plasma of recipient miR-155 KO mice. This data suggests that miR-155 from plasma of 
WT mice undergoes biodistribution in recipient miR-155 KO mice. In contrast to the rapid distribution 
of intravenous (i.v.) administered WT plasma, intraperitoneal (i.p.) route of delivery of plasma resulted in 
a lower but sustained levels of miR-155 in the plasma of recipient miR-155 KO mice even after 4h (Fig. 
3B). For the remainder of the study we used i.v administration as the i.v route of plasma administration 
was more robust than i.p. to deliver miR-155.
Next, we evaluated whether reduction in plasma miR-155 levels after minutes post injection correlated 
with distribution of miR-155 into various tissues in recipient miR-155 KO mice. After i.v. administration 
of WT plasma, we found low but detectable levels of miR-155 in the liver of recipient miR-155 KO mice 
at 40 and 60 mins (Fig. 3C). After WT plasma transferred, signal of miR-155 in organs of recipient miR-
155 KO mice was very low. Therefore, a pre-amplification of cDNA was performed to enhance miR-155 
signals by real-time PCR. To rule out blood contamination accounting for miR-155 detection in tissues, 
we perfused the livers and red blood cell (RBC) lysis was performed using RBC lysis buffer. Similar to 
non-perfused livers, miR-155 was detected at 40 and 60 mins in perfused livers of recipient miR-155 KO 
mice (Fig. 3D), suggesting the accumulation of miR-155 in the liver rather than resulting from blood 
contamination. We also found very low levels of miR-155 in adipose tissue, and lung of recipient miR-155 
KO mice (data not shown). No detectable level of miR-155 was found in kidney, thymus, bone marrow 
cells, heart, or brain of recipient miR-155 KO mice. This could be due to the fact that the injected amount 
of miR-155 was not enough to reach the detectable threshold in these organs of recipient miR-155 KO 
mice. Similarly, intraperitoneal administration of WT plasma resulted in a detectable but very low signal 
for miR-155 in the liver, and adipose tissue of recipient miR-155 KO mice (data not shown).
Discussion
Circulating miRNAs have gained increasing interest as new biomarkers of various diseases. Aberrant 
miRNA signatures have been found in various diseases including cancers, metabolic and neurologi-
cal disorders7,33. Circulating miRNAs can be packaged in extracellular vesicles including exosomes and 
microvesicles. Emerging studies suggest that extracellular miRNAs are involved in intercellular commu-
nication and exosome-mediated transfer of circulating miRNA has emerged as a new paradigm of hori-
zontal transfer6,34,35. Here we demonstrated the biodistribution of highly studied inflammation associated 
miR-155.
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We report the distribution and half-life of exosome loaded miR-155 mimic (exo-miR-155 mimic) 
using the miR-155 KO mouse model system. We established a murine B cell derived exosome-mediated 
system to deliver a miR-155 mimic (mature) into mice. We demonstrated that exo-miR-155 mimic under-
goes distribution in the recipient miR-155 KO mice very rapidly both in plasma and organs (Fig. 4). The 
half-life of exo-miR-155 mimic was short, around 5 mins. The highest amount of miR-155 was found 
in the liver followed by adipose tissue, lung and muscle and lowest in the kidney. Consistent with our 
results, previous studies have shown the tissue distribution of exogenously administered exosomes in vivo 
Figure 2. Biological function of exosome loaded miRNA-155 mimic. Hepatocytes and Kupffer cells were 
isolated from miR-155 KO mice as described in the methods. Exosomes loaded with either scrambled mimic 
or miR-155 mimic were added to cells for 6 h. Cells were washed 3 times with PBS to remove free-floating 
exosomes. Hepatocytes were lysed with Qiazole and miR-155 levels were evaluated (A) Kupffer cells were 
treated or not with LPS (100 ng/ul) for 6 h and cell-free supernatant was collected. The levels of miR-155 (B) 
MIP2 (C) and MCP1 (mRNA) were checked using real-time qPCR and levels were normalized to untreated 
cells. MCP1 protein levels were measured from cell-free supernatant (E) miR-155 levels were normalized 
to hepatocytes or Kupffer cells isolated from wild type mice. * indicates p< 0.05 scrambled loaded exosome 
treated cells and # compared to scrambled loaded exosome + LPS treated cells. SnoRNA202 (A,B) or 18S 
(C,D) was used to normalize the technical variations between the samples. ns: non significant. Statistical 
analysis was performed using non-parametric Mann-Whitney test.
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and fluorescent probe-labeled exosomes were predominantly detectable in the liver, lungs, kidneys, and 
spleen after 1h of intraperitoneal administration36,37. Our results indicate that exo-miR-155 mimic was 
delivered to hepatocytes and MNCs in vivo in the liver suggesting the potential use of exosomal-mediated 
delivery of miRNA/nucleic acids to different liver cell populations. In our study we found no significant 
accumulation of exo-miR-155 mimic in the brain. This is consistent with previous reports showing the 
delivery of exosomes into brain only after some modifications such as intranasal administration of the 
labeled exosomes37 and genetically modification of exosomes with a neuron-specific targeting peptide25. 
These studies suggest that modification either in exosomes or in delivery route is needed for successful 
delivery of exosomes into the brain. Our studies further demonstrate that exo-miR-155 mimic has a short 
half-life after systemic administration since most of exo-miR-155 mimic signal has disappeared from the 
organs and plasma after 30–40 mins post injection.
To rule out that anti-CD63 and/or anti-rabbit IgG immune complexes and/or magnetic beads do not 
account for the rapid clearance of exosomes in vivo, we carried out a pilot experiment where exosomes 
were isolated with ExoQuick only (before and after electroporation) and injected into mice for 30 mins. 
We found no differences in the kinetic of plasma levels of miR-155 in KO mice between isolation meth-
ods (anti-CD63 magnetic isolation versus ExoQuick). Consistent with our results, previous studies found 
Figure 3. Biodistribution of transferred wild type plasma in miRNA-155 KO mice. miR-155 KO mice 
(n = 6–8) were injected with ~150 ul of plasma isolated from WT mice (CpG+ LPS treated) as described in 
the methods. After systemic administration, blood was collected and mice were perfused or not as indicated. 
Plasma was isolated and miR-155 levels were determined by real-time qPCR. Due to miR-155 low signal, 
pre-amplification of cDNA from tissue samples was performed. i.v route of delivery (A) and i.p route of 
delivery (B) miR-155 levels in non-perfused (C) and perfused livers (D) miR-155 levels were normalized to 
wild type saline treated mice. Data is presented as mean ± SEM. * indicates p < 0.05 versus saline treated KO 
mice. nd: not detected. Synthetic spiked cel-miR-39 (A,B) or SnoRNA202 (C,D) was used to normalize the 
technical variations between the samples. Statistical analysis was performed using non-parametric Mann-
Whitney test.
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that exosomes delivered to mice are rapidly cleared from the systemic circulation38–42. It was further 
demonstrated that hepatic and splenic macrophages take up exosomes administrated by intravenous 
injection. It was also suggested that the liver is involved in clearing of exosomes due to their negative 
charge using the same mechanism as in clearance of negatively charged liposomes39. These exosomes 
were prepared using ultracentrifugation method38,39. These studies including our pilot study rules out 
any possibility that rapid clearance of exosomes is due to anti-CD63/ or anti-IgG immune complexes or 
magnetic beads.
The advantage of exosome-mediated delivery of miR-155 mimic was that exosomes can be stored 
frozen (− 80 °C) for a prolonged time and are stable and ready to use without the need of immediate 
processing prior to administration. Also we found no inflammatory response in mice administered with 
scrambled mimic loaded exosomes suggesting the safe efficacy of exosomes for in vivo studies.
While electroporation of exosomes with miRNA or siRNA has been reported in the literature25, a 
more detailed study demonstrated that the majority of the siRNA precipitated outside exosomes and 
co-purified with exosomes43. We have used EDTA in our electroporation buffer and according to 
Kooijman et al there is less aggregation of miRNA in the presence of EDTA in electroporation buffer43. 
Moreover, RNAse A treatment performed after electroporation was able to degrade free floating miR-155 
as we found difference in the amount of miR-155 in the exosomes before and after RNAse A treatment. If 
there are some miRNA aggregates attached to exosomes, it is likely that endogenous RNAse will degrade 
naked miRNA after administration to mice in our experimental conditions. There is no clear evidence if 
vesicular associated miRNA are either inside or just adhere to vesicles under in vivo conditions.
It has been demonstrated that chemically synthetic small RNA are instable in the serum44. miR-155 
mimic used in our experiments has no chemical modifications such as LNA, o-methyl etc and naked 
miRNA is prone to degradation in the presence of RNAse and only miRNA associated with vesicles or 
proteins are resistant to RNAse digestion2,5. A recent study demonstrated that number of given miRNA 
in exosomes was less than one molecule45. These exosomes were isolated from normal human plasma, 
dendritic cells and ovarian cancer cells45. It is noteworthy to mention that in our experimental condi-
tions we used higher amounts of miRNA mimic for electroporation into exosomes. The reason for using 
higher miRNA-155 amount was to have sufficiently levels to be able to detect in miR-155 KO mice after 
injection and follow its biodistribtuion.
Previously we showed induction of miR-155 in plasma (WT plasma) and circulating miR-155 was 
mostly fractionated with extracellular vesicles after CpG (TLR9 ligand) and LPS (TLR4 ligand) treat-
ment in mice29. In the present study, we showed that delivery of WT plasma resulted in a rapid and 
robust accumulation of miR-155 in the plasma of recipient miR-155 KO mice. We provided evidence that 
injected miR-155 from WT plasma is distributed to the liver in recipient miR-155 KO mice. The half-life 
of donor plasma miR-155 in recipient miR-155 KO mice was around 30 mins. Our use of miR-155 KO 
mouse model system to study biodistribution of natural circulating miRNA/EV-associated miRNA could 
be applied to study distribution of other miRNA in future. Our results also indicated that the i.v route of 
plasma administration was more robust in comparison to the i.p mode of delivery. This observation was 
consistent with previous observation46. The differences in miR-155 levels with i.v. and i.p injections could 
also reflect miR-155 stability. However, there is not much known about the stability of circulating miRNA 
in vivo. One possibility could be that ip mode of administration releases miRNA slowly and accounts for 
the detection of miR-155 after 240 mins. Another possibility could be that vesicular associated miR-155 
is retained more efficiently with i.p. than i.v. mode of administration. Vesicular associated miRNAs were 
shown to have increased stability47.
Figure 4. Summary of miR-155 biodistribution. 
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The advantage of using plasma miR-155 from wild type mice is that it contains miR-155 in both ves-
icles and non-vesicular forms29. The disadvantage is that CPG+ LPS stimulation that facilitates miR-155 
enrichment, also results in increased levels of cytokines/chemokines in the plasma48. Nevertheless, there 
is no evidence that carryover of cytokines would modulate the biodistribution of miR-155 in recipient 
miR-155 KO mice. Another limitation of using WT plasma was that the amount of miR-155 delivered 
to recipient miR-155 KO mice was very low. This limitation could be overcome by repeated injections 
(daily) of WT plasma over time to restore miR-155 to physiological levels to evaluate the biological role 
of WT circulating miR-155.
Biodistribution and dynamics of WT plasma were similar to that of exosome mediated delivery of 
miR-155, suggesting that both delivery modes have similar biodistribution profiles. However, we found 
the half-life of transferred plasma miR-155 was longer compared to exosome-loaded miR-155 in recipi-
ent miR-155 KO mice. This could be because exosomes are cleared faster in the liver39. Also WT plasma 
contains miR-155 both in EVs and non-vesicular forms29, which could account for increased stability of 
transferred plasma miR-155 in vivo.
Extracellular miRNAs have been reported to be involved in intercellular communication11–13. Indeed, 
exo-miR-155 mimic were readily taken up by primary mouse hepatocytes and Kupffer cells (KCs) iso-
lated from miR-155 KO mice in vitro co-culture. Exosomal uptake was more efficient in Kupffer cells 
than hepatocytes. As highly proficient phagocytic cells, KCs are readily capable of uptake of micropar-
ticles49. This was in contrast to in vivo findings where relative miR-155 expression in hepatocytes was 
higher than MNCs isolated from recipient miR-155 KO mice. MNCs represented different liver popu-
lation including monocytes, lymphocytes and dendritic cells and this could account for lower miR-155 
expression in vivo. Of note: miR-155 basal expression is higher in KCs than hepatocytes in wild type 
mice50. The mechanisms of uptake of exosomes by cells likely varies with the cell type. In many pathways 
of uptake, exosomes will be trapped in the endosomes or lysosomes and eventually degraded51. Our 
results also indicate that miR-155 levels were different between total liver and isolated hepatocytes and 
MNCs in vivo. These differences could be attributed to different baseline expression of miR-155 in the 
wild type liver (Cq 33), isolated hepatocytes (Cq 32) and MNCs (Cq28). Another reason could be that 
the liver is composed of various cell population (Kupffer cells, dendritic cells, T cells, endothelial cells, 
NK, NKT) and it is likely that injected miR-155 is not only taken up by the hepatocytes and MNCs but 
also by other liver cells.
Our results indicate that miR-155 delivered by exosomes has functional effects in KCs as restoration 
of miR-155 in KCs isolated from miR-155 KO mice after co-culture with exo-miR-155 mimic resulted 
in pro-inflammatory gene induction after LPS treatment. We found only a moderate increase in these 
cytokines after introduction of exo-miR-155 mimics suggesting that KCs isolated from miR-155 KO 
mice had some defects in LPS signaling. This suggests that if exogenous miR-155 could be delivered 
in sufficient amounts it could be possible that KCs might take enough to have functional effect in vivo. 
Though our in vitro findings suggest that miR-155 loaded exosomes have a specific effect on MCP1, we 
cannot rule out the possibility that miR-155-electroporated exosomes could have multiple non-specific 
effects, including on innate immunity or by competition with miRNA, Ago proteins and other miRNA 
processing proteins in exosomes52.
In summary, the information in our study about the pharmacokinetics of plasma and exosome loaded 
miR-155 (Fig. 4) will help in developing exosome-mediated miRNA delivery and investigating the bio-
logical function in vivo. Future studies will be able to provide more information about other circulating 
miRNA distribution and function resulting in a better understanding of the role of these entities in vivo.
Methods
All methods were carried out in accordance with the approved guidelines.
Animal studies. Mice deficient in miRNA-155 (miR-155 KO) were obtained from Jackson Laboratory 
and the colony was maintained in the animal facility at the University of Massachusetts Medical School. 
Eight to ten week old C57/Bl6J wild type (WT) male or female mice were obtained from Jackson 
Laboratory. All experimental protocols were approved by the Institutional Animal Use and Care 
Committee of the University of Massachusetts Medical School (Worcester, MA). To induce the miR-155 
induction in the circulation, wild type female mice were either injected with saline or 2.5 mg/kg CpG 
(i.p) for three days as described53. On day 4, CpG treated mice received 0.5 mg/kg LPS (i.p.) 3 h prior to 
sacrifice. At the end of treatment, mice were cheek bled and plasma was separated and stored at − 80 °C 
for further analyses. Liver and other tissue was washed with PBS and immediately either snap frozen in 
liquid nitrogen (protein analyses) or in RNA later (Qiagen) (RNA analyses) respectively.
To separate the plasma, blood was collected in EDTA containing microtainer tubes (BD Biosciences) 
and centrifuged at 5000 g for 10 mins at room temperature. The centrifugation step was repeated twice 
to minimize platelet contamination and the clear plasma fraction was aliquoted and stored at − 80 0C.
Exosome isolation from tissue culture media. Exosomes were generated from the murine B cell 
line (M12.4.1). B cells were cultured in RPMI medium supplemented with 10% FBS and 1% penicil-
lin/streptomycin. To induce exosome release, the cells were cultured in exosome-depleted FBS (System 
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Biosciences, USA) medium stimulated with IL-4 (50 ng/mL)+ CD40 (5 μ g/mL) for 3 days as described54. 
IL-4 and CD40 treatment was used to increase exosome production as reported previously54.
For the isolation of exosomes, culture medium was centrifuged at 500 g for 10 mins to deplete cells and 
then at 10,000 g for 20 mins to eliminate residual cellular debris as described previously22. The resulting 
supernatant was passed through 0.4 μ m and 0.22 μ m filters and concentrated using the Amicon Ultra-15 
Centrifugal Filter Unit with Ultracel-100 membrane (Millipore, MA). CD63 enriched exosomes were iso-
lated using anti-CD63 immuno-magnetic positive selection as described32. Anti-CD63 antibody (Abcam 
cat. #ab8219 and Santa Cruz cat. #15363) was used as primary antibody followed by corresponding 
secondary antibody coupled with magnetic beads (Miltenyl biotech cat. #130-048-602). Exosomes were 
eluted from anti-CD63 beads using elution buffer from Invitrogen and finally exosomes were resus-
pended in PBS. The Miltenyl Biotec midi-MACS separator along side LS columns (cat. #130-042-901) 
was used.
The exosomes were quantified using NanoSight LM10 system (NanoSight, UK) equipped with a 
fast video capture and Nanoparticle Tracking Analysis system (NTA), according to the manufacturer’s 
instructions. The samples were measured for 60s at room temperature with manual shutter and gain 
adjustments. NTA was used to measure particle size (measured in nanometers) and concentration of 
particles (particles/ml). Each measurement was repeated for three times.
Electron Microscopy. For electron microscopy, exosomes were re-suspended in PBS and placed on a 
formvar-coated copper grid and incubated for 30 mins as described22. The grid was washed with PBS and 
sample was fixed by placing the grid on the top of the 2% paraformaldehyde placed on the parafilm for 
10 mins. Fixation was followed by several washes with deionized water and samples contrasted by add-
ing 2% uranyl acetate for 15 mins. Samples were embedded by adding a drop of 0.13% methyl cellulose 
and 0.4% uranyl acetate for 10 mins. The grid was examined in a Philips CM10 transmission electron 
microscope and images were captured using a Gatan CCD digital camera.
Western Blotting. Western blot analysis was carried out for exosomal and non-exosomal markers. 
Exosomes or B cells were lysed with RIPA buffer and 30 μ g of protein from each fraction was run on 
10% SDS-PAGE gel. Proteins were transferred to nitrocellulose membrane and were blocked in TBS 
containing 5% non-fat dry milk and 0.1% Tween-20 for 1 hour followed by incubation with primary 
CD63 or CD81 or GRP78 antibody at 4°C for overnight. Next day, membranes were washed 3 times with 
TBST and then incubated with corresponding horseradish peroxidase-conjugated secondary antibodies 
for 1 hour at room temperature (Santa Cruz Biotechnology). The target proteins were visualized on blot 
using a Clarity™ Western ECL substrate kit (BioRad) according to the manufacturer’s protocol and ana-
lyzed via Fujifilm LAS-4000 luminescent image analyzer.
Loading of miR-155 mimic into exosomes. The loading of exosomes with miRNA-155 mimic or 
scrambled mimic was performed based on our previously optimized protocol22. Briefly, resuspended 
exosomes were diluted in the Gene Pulser electroporation buffer (Bio-Rad Laboratories, CA) in 1:1 ratio. 
Mouse miRNA-155 mimic (Ambion, NY) or scrambled miRNA mimic control#1 (scrambled mimic) at 
final concentration of 5 μ mol/ml were added to 200 μ l of exosome sample containing 1 μ g/μ l exosomal 
protein using standardized conditions as we previously described22. Approximately 1 μ mole of miRNA 
is loaded into 200 μ l of exosome fractions, containing about 4 × 108 particles (exosomes). The mixtures 
were transferred into cold 0.2cm electroporation cuvettes and electroporated at 150 V/100 μ F capacitance 
using a Gene pulser II System (Bio-Rad Laboratories, CA). Immediately after electroporation, the mix-
ture was treated with one unit of RNase A (Qiagen, Germany) for 30 mins to remove the free-floating 
miRNA mimic. Deactivation of RNase A was achieved by adding 2 μ l of RNase inhibitor (Life technol-
ogies) and exosomes were re-isolated using ExoQuick-TC™ reagent as described by the manufacturer. 
The final pellet (exosome) was resuspended in PBS, aliquoted in 100 μ l volume to avoid freeze and thaw 
cycles and stored at − 80 °C. Of note, freeze and thaw of exosomes (2 times) did not influence miR-155 
levels significantly.
Delivery of WT plasma or miR-155 mimic loaded exosomes. Prior to injecting into recipient 
miR-155 KO mice, WT plasma (miR-155 enriched) or miR-155 mimic loaded exosomes (exo-miR-155 
mimic) or scrambled loaded exosomes were brought to room temperature (thaw) and vortexed gently 
to make a homogenous suspension. 150 μ l of WT plasma or 100 μ l exosomes either containing miR-
155 mimic or scrambled mimic was injected into recipient miR-155 KO mice (intraperitoneal [i.p.] or 
intravenous [i.v.]) for various times. Blood was drawn and animals were perfused using our laboratory 
standardized protocol55. To rule out any blood contamination red blood lysis buffer (Sigma, USA) was 
used as per manufacture’s instructions.
Tissue collection, perfusion and cell isolation. At the conclusion of the experiment, various organs 
were removed, immediately washed in PBS, blotted on tissue and stored in RNA later at − 80 °C. To iso-
late the different liver cell populations, some mice were perfused using the laboratory protocol55. Briefly, 
mice were anesthetized with ketamine and the livers were perfused with saline solution for 10 mins fol-
lowed by in vivo digestion with HBSS solution containing collagenase for 5 mins. The perfused liver was 
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placed into petri dish containing HBSS and collagenase and cells were released by separating the liver 
lobes. To separate hepatocytes, cell suspension was centrifuged at 200 g for 5 mins at room temperature. 
The pellet containing hepatocytes was washed 2 times with PBS and cultured in low DMEM medium 
(10% FBS+ antibiotics) containing insulin as described55. To isolate mononuclear cells (MNCs), superna-
tants were centrifuged at 1200 g for 10 mins and pellet was suspended in PBS and washed two times. Red 
blood lysis buffer (Sigma, USA) was used to remove blood contamination as per manufacture’s instruc-
tions. The resulting pellet was suspended in 40% percoll and layered on 70% percoll and centrifuged at 
2000 g for 25 mins at room temperature. The interphase containing mononuclear cells were collected 
and washed with PBS 2 times and cultured in 10% low glucose DMEM containing antibiotics. Kupffer 
cells (KCs) were isolated as described previously using an established protocol28. Briefly, after 10 mins 
perfusion of liver with saline solution, in vivo digestion was done using liberase enzyme for 5 mins and 
followed by in vitro digestion for 30 mins. The non-hepatocyte fraction was separated by Percoll gradient 
and centrifuged at 1600 g for 30 mins. The inter-cushion layer was collected, washed with PBS two times 
and cultured in low glucose DMEM supplemented with 10% FBS and antibiotics. The non-adherent 
cells were removed after 3–4 h of plating with PBS and new medium was added. The KCs were used for 
subsequent experiments.
In vitro co-culture of exosomes. To understand the biological effect of exo-miR-155 mimic, we 
performed in vitro studies. Primary hepatocytes, and Kupffer cells (KCs) were isolated from miR-155 
KO mice and cultured with either control mimic or miR-155 mimic loaded exosomes (~2 × 108 parti-
cles/ml) for 6 h. After incubation, cells were washed twice with PBS to remove free-floating exosomes. 
KCs were counted and plated onto 96 well plates (@1 × 106 cells/ml) and stimulated with or without LPS 
(100 ng/ml) for 6 h. The supernatants were collected and centrifuged to remove the cell debris and used 
for MCP1 ELISA.
RNA isolation and PCR analysis. 10–20 mg of each organ was homogenized in QIAzol Lysis reagent 
(Qiagen, Germany) using stainless steel beads in TissueLyser II (Qiagen, USA). Total RNA was isolated 
using Direct-zol RNA MiniPrep kit with on column DNA digestion (Zymo Research Corp., USA). For 
mRNA analysis, cDNA synthesis was carried out using iScript reverse transcription system kit (BioRad, 
USA) and quantitative analyses of genes were performed using gene-specific primers on a Bio-Rad iCy-
cler real time machine. Primer sequences for TNFα , MCP1, IL-1β and 18S were same as described28. 
Cq value was normalized to 18S and fold change was calculated using the delta-delta Ct method. For the 
detection of miRNAs, TaqMan miRNA Assays (Applied Biosystems) were employed as described previ-
ously28. SnoRNA202 (tissue/cells) or synthetic cel-miR-39 (exosomes and plasma) was used to normalize 
the technical variations between the samples. To enhance miR-155 signal in recipient miR-155 KO mice 
after the administration of WT plasma (miR-155 enriched) a pre-amplification step was introduced. The 
cDNA was pre-amplified using pre-amplification kit as described by the supplier (Applied Biosystem, 
USA) and diluted pre-amplified product was used for real time PCR.
Enzyme-linked Immunosorbent Assay (ELISA). Supernatants were collected from cultured KCs 
after co-culture and centrifuged at 2000 g for 10 mins to remove cellular debris and were frozen at − 80 °C 
until use. Protein levels of TNFα , IL-1β and MCP1 were measured from cell-free culture supernatant by 
ELISA. The quantification of TNFα (BioLegends, San Diego, CA), MCP1 (BioLegend Inc., San Diego, 
CA) and IL-1β (R&D Systems, Inc., Minneapolis, MN) were carried out based on manufacturers’ rec-
ommendations using an ELISA reader.
Statistical analysis. Statistical analysis was performed using non-parametric Mann-Whitney test. 
Data is shown as average ± standard error of the mean (SEM) and differences were considered statisti-
cally significant at p ≤ 0.05.
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